AR047530A1 - Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida - Google Patents

Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida

Info

Publication number
AR047530A1
AR047530A1 ARP050100395A ARP050100395A AR047530A1 AR 047530 A1 AR047530 A1 AR 047530A1 AR P050100395 A ARP050100395 A AR P050100395A AR P050100395 A ARP050100395 A AR P050100395A AR 047530 A1 AR047530 A1 AR 047530A1
Authority
AR
Argentina
Prior art keywords
salt
methyl
phenyl
tartrate
methylipiperazin
Prior art date
Application number
ARP050100395A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR047530(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR047530A1 publication Critical patent/AR047530A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente se refiere a sales de adicion de ácido de 4-[(4-metil-1-piperazinil)metil-N-[4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]fenil]-benzamida, las cuales son seleccionadas del grupo que consiste en una sal tartrato, tal como una sal (D)(- ) tartrato o una sal (L)(+)tartrato, una sal cloridrato, una sal citrato, una sal malato, una sal fumarato, una sal succinato, una sal benzoato, una sal bencensulfonato, una sal pamoato, una sal formiato, una sal malonato, una sal 1,5- naftalenodisulfonato, una sal salicilato, una sal ciclohexansulfamato, una sal lactato, particularmente una sal (S)-lactato, una sal mandelato, una sal glutarato, una sal adipato, una sal escuarato, una sal vainillato, una sal oxaloacetato, una sal ascorbato y una sal sulfato.
ARP050100395A 2004-02-04 2005-02-02 Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida AR047530A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54181704P 2004-02-04 2004-02-04

Publications (1)

Publication Number Publication Date
AR047530A1 true AR047530A1 (es) 2006-01-25

Family

ID=34837520

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100395A AR047530A1 (es) 2004-02-04 2005-02-02 Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida

Country Status (22)

Country Link
US (3) US20080249104A1 (es)
EP (1) EP1713792B1 (es)
JP (1) JP4937760B2 (es)
KR (2) KR20120127525A (es)
CN (1) CN100558723C (es)
AR (1) AR047530A1 (es)
AU (1) AU2005211514B2 (es)
BR (1) BRPI0507464A (es)
CA (1) CA2553887C (es)
EC (1) ECSP066752A (es)
IL (1) IL177005A (es)
MA (1) MA28428B1 (es)
MY (1) MY144177A (es)
NO (1) NO20063942L (es)
NZ (1) NZ548714A (es)
PE (1) PE20051096A1 (es)
PH (1) PH12013500157A1 (es)
RU (1) RU2375355C2 (es)
TN (1) TNSN06243A1 (es)
TW (1) TWI347186B (es)
WO (1) WO2005075454A2 (es)
ZA (1) ZA200605972B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
KR20130137721A (ko) 2005-11-25 2013-12-17 노파르티스 아게 이마티니브 메실레이트의 ｆ, ｇ, ｈ, ｉ 및 ｋ 결정형
KR100799821B1 (ko) * 2007-02-05 2008-01-31 동화약품공업주식회사 신규한 이마티닙 캠실레이트 및 그의 제조방법
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
WO2008136010A1 (en) * 2007-05-07 2008-11-13 Natco Pharma Limited A process for the preparation of highly pure imatinib base
WO2009036753A2 (de) * 2007-09-20 2009-03-26 Schebo Biotech Ag Neue pharmazeutika, verfahren zu ihrer herstellung und ihre verwendung in der medizinischen therapie
KR101041203B1 (ko) 2007-09-25 2011-06-13 테바 파마슈티컬 인더스트리즈 리미티드 안정한 이매티닙 조성물
EP2062885A1 (en) * 2007-11-21 2009-05-27 Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. Acid addition salts of imatinib and formulations comprising the same
KR20210151988A (ko) 2009-01-16 2021-12-14 엑셀리시스, 인코포레이티드 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
US20100189790A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US20100330130A1 (en) * 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
CA2766088C (en) 2009-06-25 2017-06-13 Alkermes, Inc. Heterocyclic compounds for the treatment of neurological and psychological disorders
EP2482820A2 (en) 2009-09-28 2012-08-08 Medizinische Universität Wien New use of pdgfrbeta inhibitors
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
KR101138840B1 (ko) * 2009-12-28 2012-05-10 주식회사 셀트리온화학연구소 이마티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물
CA2792472A1 (en) 2010-03-15 2011-09-22 Natco Pharma Limited Process for the preparation of highly pure crystalline imatinib base
EP2582689B1 (en) 2010-06-18 2017-03-01 KRKA, D.D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
BR122022008957B1 (pt) 2012-04-04 2023-02-07 Intervet International B.V Composições veterinárias mastigáveis macias sólidas compreendendo um ingrediente ativo isoxazolina
WO2014016848A2 (en) 2012-07-24 2014-01-30 Laurus Labs Private Limited Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
WO2015017728A1 (en) 2013-07-31 2015-02-05 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
EP3407874B1 (en) 2016-01-25 2024-05-22 KRKA, d.d., Novo mesto Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (es) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
JP3691861B2 (ja) * 1994-09-14 2005-09-07 株式会社東芝 光ディスク用光パルス幅制御装置
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6448293B1 (en) * 2000-03-31 2002-09-10 Pfizer Inc. Diphenyl ether compounds useful in therapy
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
US6479692B1 (en) * 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
WO2003077892A2 (en) * 2002-03-15 2003-09-25 Novartis Ag 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for treating ang ii-mediated diseases
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
KR20130137721A (ko) * 2005-11-25 2013-12-17 노파르티스 아게 이마티니브 메실레이트의 ｆ, ｇ, ｈ, ｉ 및 ｋ 결정형

Also Published As

Publication number Publication date
PH12013500157A1 (en) 2014-09-08
AU2005211514A1 (en) 2005-08-18
KR20120127525A (ko) 2012-11-21
EP1713792B1 (en) 2014-04-30
US20140051853A1 (en) 2014-02-20
US20080249104A1 (en) 2008-10-09
IL177005A0 (en) 2006-12-10
RU2375355C2 (ru) 2009-12-10
JP2007520518A (ja) 2007-07-26
KR20060135735A (ko) 2006-12-29
WO2005075454A2 (en) 2005-08-18
MA28428B1 (fr) 2007-02-01
NO20063942L (no) 2006-11-02
TNSN06243A1 (en) 2007-12-03
BRPI0507464A (pt) 2007-07-10
EP1713792A2 (en) 2006-10-25
US20120142697A1 (en) 2012-06-07
ZA200605972B (en) 2007-11-28
ECSP066752A (es) 2006-11-16
AU2005211514B2 (en) 2009-09-10
CA2553887C (en) 2013-04-16
TW200529854A (en) 2005-09-16
CN100558723C (zh) 2009-11-11
TWI347186B (en) 2011-08-21
RU2006131548A (ru) 2008-03-10
US8513256B2 (en) 2013-08-20
MY144177A (en) 2011-08-15
CN1914191A (zh) 2007-02-14
WO2005075454A3 (en) 2006-07-27
IL177005A (en) 2014-05-28
NZ548714A (en) 2009-08-28
PE20051096A1 (es) 2006-01-23
CA2553887A1 (en) 2005-08-18
JP4937760B2 (ja) 2012-05-23

Similar Documents

Publication Publication Date Title
AR047530A1 (es) Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida
UA84462C2 (ru) Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
TR200701870T1 (tr) İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem.
EA201000145A1 (ru) Кристаллические формы 4-метил-n-[3-(4-метилимидазол-1-ил)-5-трифторметилфенил]-3-(4-пиридин-3-илпиримидин-2-иламино)бензамида
EA200702541A1 (ru) Полиморфы этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты
DE602005015862D1 (de) Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien
IL223350A0 (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
AR076433A1 (es) Sales inhibidoras de cdk
PE20070795A1 (es) Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
PE20070004A1 (es) Imidazoquinolinas como inhibidores de quinasa de lipido
PE20061394A1 (es) Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas
PE20121476A1 (es) Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r
ATE504580T1 (de) Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit
AR057566A1 (es) 2- acilaminotiazol -4- carboxamidas insecticidas
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
NO20080144L (no) Spiro-benzimidazoler som inhibitorer av magesyre og sekresjon
BR112023004656A2 (pt) Formas cristalinas e amorfas de um composto para a degradação direcionada do receptor de estrogênio
HK1083492A1 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
ATE509619T1 (de) Herstellungsverfahren für eine feste dispersion mit itraconazol
DE602006003225D1 (de) Chlorsubstituierte guanidine
ATE492277T1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-( -(pyridin-3-yl)pyrimidin-2- ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms
TH74677A (th) รูปเกลือของ 4-[(4-เมทธิลปิปเปอราซิน-1-อิลเมทธิล)-n-[4-เมทธิล-3-(4-ไพริดิน-3-อิล)ไพริมิดิน-2-อิลอะมิโน)เฟนนิล]-เบนซามีด
UY28498A1 (es) Modificación de cristal de un derivado de n-fenil-2-pirimidinamina, procesos para su fabricación y su uso.
TH74677B (th) รูปเกลือของ 4-[(4-เมทธิลปิปเปอราซิน-1-อิลเมทธิล)-n-[4-เมทธิล-3-(4-ไพริดิน-3-อิล)ไพริมิดิน-2-อิลอะมิโน)เฟนนิล]-เบนซามีด
ATE480534T1 (de) Kristallines variables hydrat von (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxy ropyl)amino)-2- methylpropyl)phenoxy)-3-pyridincarbonsäureamid- hemisuccinatsalz

Legal Events

Date Code Title Description
FA Abandonment or withdrawal